Q/C Technologies (QCLS) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q/C Technologies is the larger company by market cap ($5.2 million vs $2.7 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QCLS | VRAX |
|---|---|---|
| Share price | $0.6367 | $1.99 |
| Market cap | $5.21M | $2.68M |
| 1-day change | +0.74% | -5.69% |
| P/E ratio (TTM) | 0.24 | — |
| EPS (TTM) | $2.62 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.17 | $21.75 |
| 52-week low | $0.42 | $1.83 |
| Distance from 52-week high | -92.21% | -90.85% |
| Average volume | 4.98M | 650.11K |
| Shares outstanding | 8.19M | 1.34M |
| Employees | 3 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Q/C Technologies
QCLS stock →Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 3 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 26 employees
QCLS vs VRAX FAQ
Which is bigger, Q/C Technologies or Virax Biolabs Group?
Q/C Technologies (QCLS) is larger, with a market capitalization of $5.21M compared with $2.68M for Virax Biolabs Group (VRAX).
Are Q/C Technologies and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.